| Abstrakt: |
A new report discusses research findings on heart failure and the use of remimazolam, a new ultrashort-acting benzodiazepine anesthetic. The study, conducted at Kindai University Faculty of Medicine in Osaka, Japan, aimed to assess the efficacy and safety of remimazolam in maintaining hemodynamic stability during anesthetic induction and maintenance in patients with severe mitral regurgitation and low left ventricular function. The results showed that remimazolam can be safely used in these patients without major hemodynamic concerns. This information may be useful for individuals researching anesthesia and cardiovascular conditions. [Extracted from the article] |
